Results 61 to 70 of about 52,325 (288)

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan   +2 more
wiley   +1 more source

Recurrent aphthous stomatitis in a patient with Wilson's disease [PDF]

open access: yes, 2019
La estomatitis aftosa recurrente es la enfermedad ulcerativa más común de la mucosa oral. Ocurre mayormente en adultos jóvenes sanos, afectando al 20% de la población general. Se ha propuesto que puede deberse a alteraciones tanto locales como sistémicas,
Aguerre, María Florencia   +3 more
core  

Herpes zoster in an immunocompetent adolescent – A case of rare occurrence

open access: yesJournal of Family Medicine and Primary Care
Herpes zoster is an acute viral infection caused by the reactivation of the varicella zoster virus. It occurs commonly in immunocompromised adults. Odontalgia may be an early prodromal symptom when herpes zoster involves the oral and maxillofacial region,
A.Winnifred Christy   +3 more
doaj   +1 more source

Herpes zoster: Epidemiological Features of the Incidence in 2019

open access: yesЭпидемиология и вакцинопрофилактика, 2020
The urgency of the problem of herpes zoster (shingles) consists in its wide distribution in the world, high incidence rates in a significant part of the subjects of the Russian Federation, as well as the severity of complications caused by this infection.
A. N. Kaira, V. F. Lavrov
doaj   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni   +6 more
wiley   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal   +2 more
wiley   +1 more source

Construction of risk prediction model for postherpetic neuralgia of patients with herpes zoster

open access: yesHuli yanjiu, 2022
ObjectiveTo analyze the risk factors of postherpetic neuralgia(PHN) of patients with herpes zoster and to construct risk prediction model.Methods425 patients with herpes zoster admitted to department of dermatology of our hospital were selected as study ...
LI Jiao, HUANG Guohui, NI Ping
doaj  

Incidence of Herpes Zoster in relationship with Climate Factors from 2009 to 2011

open access: yesAlthea Medical Journal, 2015
Background: Herpes zoster, or shingles, is a skin or mucous infection caused by the reactivation of varicella-zoster virus (VZV). Seasonal pattern of herpes zoster incidence was reported in some countries, indicating that emergence of this disease was ...
Herning Adinda   +2 more
doaj   +1 more source

Ann Epidemiol [PDF]

open access: yes
PurposeTo describe self-reported herpes zoster (HZ) and explore factors that could impact interpretation of results from health care\u2013based HZ studies.MethodsWe performed logistic regression using data from the 2008 Health and Retirement Study (HRS ...

core  

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy